Talphera (NASDAQ:TLPH) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Talphera (NASDAQ:TLPH) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $4.00 target price on the stock.

Several other research firms have also recently weighed in on TLPH. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Talphera in a research report on Tuesday, January 21st. Maxim Group raised Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Talphera Trading Down 1.0 %

TLPH stock opened at $0.69 on Tuesday. The firm’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.81. The company has a market capitalization of $11.82 million, a price-to-earnings ratio of -1.01 and a beta of 0.28. Talphera has a 52 week low of $0.50 and a 52 week high of $1.61.

Institutional Investors Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC acquired a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera at the end of the most recent quarter. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.